References
- Cervantes F, Dupriez E, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895–2901.
- Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
- Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
- Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–1735.
- Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 world health organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–655.
- Fisher RA. On the interpretation of x^2 from contingency tables, and the calculation of P. J R Stat Soc. 1922;85:87–94.
- Larnte K. Small samples comparisons of exact level for chi-squared goodness-of-fit statistics. J Am Stat Assoc. 1978;734:253–263.
- Bjom ME, Holmstrom MO, Hasselbalch HC. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leuk Lymphoma. 2016;57:125–128.
- Ellis MH, Lavi N, Mishchenko E, et al. Ruxolitinib treatment for myelofibrosis: efficacy and tolerability in routine practice. Leuk Res. 2015;39:1154–1158.
- Shanavas M, Popat U, Michaelis LC, et al. Outcome of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase ½ inhibitors. Biol Blood Marrow Transplant. 2016;22:432–440.
- Mascarenhas J. Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2015;2015:329–339.
- Davis KL, Coté I, Kaye JA, et al. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015;2015:848473. doi: 10.1155/2015/848473.
- Ho PJ, Marlton P, Tam C, et al. Practical management of myelofibrosis with ruxolitinib. Intern Med J. 2015;45:1221–1230.
- McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26–32.